ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET
Company Participants
Jennifer Bath - CEO
Kristin Taylor - CFO
Conference Call Participants
Swayampakula Ramakanth - H.C. Wainwright
Operator
Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies First Quarter Fiscal Year 2025 Earnings Call. We appreciate your time and interest in our company.
Today's call will be led by our CEO, Dr. Jennifer Bath; and our CFO, Kristin Taylor. They will provide a review of our financial performance, strategic initiatives and key operational highlights for the quarter.
Please note that a copy of today's presentation, along with our financial statements will be available on our company website for your reference. We encourage you to review these materials to gain a deeper understanding of our performance and strategic direction. Once again, thank you for joining us today. We look forward to sharing our progress and discussing our future plans with you.
Before we proceed, I would like to remind everyone that today's discussion will contain forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to various factors, including, but not limited to changes in market conditions, regulatory changes and other unforeseen business risks. Please note that these forward-looking statements are made as of today and we undertake no obligation to update them as a result of new information or future events unless required by law. We strongly advise all participants to refer to our filings with the Securities and Exchange Commission, SEC, including our most recent Form 20-F, and other periodic reports for a more detailed discussion of these risks and uncertainties and for a more complete understanding of the risks inherent in our business operations and the potential impact on our future performance. We appreciate your continued interest in ImmunoPrecise Antibodies.
It is now my pleasure to turn today's call over to Dr. Jennifer Bath, CEO. Please go ahead.
Jennifer Bath
Thank you, Regina, and good morning everyone, and welcome to all of you for joining us this quarterly update. Our update this morning will be brief as we recently held a fiscal year-end earnings call. As always, we greatly appreciate your time and your interest in ImmunoPrecise Antibodies.
Let me start with a brief overview and a reminder of our core strategy and business model. Pharmaceutical and biotech companies face increasing challenges in antibody drug development as they take on ever more complex targets and diseases. AI solutions, such as large language models, help accelerate lead identification, improve HYFT quality, and reduce costs enabling faster identification of high affinity antibodies and reducing clinical trial timelines, giving companies a competitive edge in personalized medicine.